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Summary Using a recently developed model for studying the biology of locally recurrent (LR) mammary
tumours in the 13762NF rat mammary adenocarcinoma system, we examined the sensitivity to polymorpho-
nuclear cell, macrophage and natural killer cell cytolysis. The parental MTF7(T20) cell line; the 'primary'
tumours which arose following subcutaneous inoculation into the mammary fat pad, scl and sc3; and the
local recurrences (following surgical excision) LRI and LRla from scl, and LR3 from sc3 were all cells
generally resistant to specific PMN cytolysis. LPS-activated macrophages caused 25.1%, 38.7% and 58.8%
specific cytolysis in MTF7, scl and LRI cells, respectively at E:T of 20:1 and 72h co-incubation. LRla, sc3
and LR3 lysis ranged from 0-4.4% under the same conditions. Non-activated macrophages did not lyse any
of the cell lines. Locally recurrent and 'primary' tumour cell lines were also not lysed by naive NK cells
(range 0.5-4.0% cytolysis). NK cells activated with bropirimine, a potent immunomodulator currently being
studied in clinical trials, and/or interleukin-2 were mildly more effective at killing LR cells. Our results show
that locally recurrent tumours exhibit heterogeneous sensitivities and are different from 'primary' tumour cells
in sensitivities to immune cell killing, but they are not necessarily more or less sensitive. Results with
bropirimine-activated or IL-2-activated NK cells emphasize that nonspecific activation is insufficient to
eliminate all tumour subpopulations.
Local recurrence of breast carcinoma occurs in approxi-
mately 10-40% of patients initially treated with modified or
radical mastectomies, depending upon a number of para-
meters including: nodal involvement at the time of surgery,
primary tumour size and location, histologic type, whether
primary and/or adjuvant therapy was administered and level
of differentiation (Donnegan et al., 1966; Fisher et al., 1977;
Toonkel et al., 1983). Often regional relapse indicates a poor
5- or 10-year prognosis because systemic disease occurs
shortly after diagnosis (Recht et al., 1985; Karabali-
Dalamaga et al., 1978; Patanaphan et al., 1984; Pearlman &
Jochimsen, 1979). Also sensitivity to treatment regimens are
frequently different in recurrent tumours compared to the
original primary tumour.
We have recently developed a model for examining factors
important in the biology of mammary tumours which
recurred following surgical excision of the primary 13762NF
mammary adenocarcinoma tumour MTF7 (Estrada et al.,
1986). We have shown that cell lines derived from local
recurrences exhibit heterogeneity in metastatic potentials
(Estrada et al., 1986), sensitivities to the commonly used
chemotherapeutic agents Adriamycin and 5-fluoro-2'-deoxy-
uridine (FUdR) and ionizing radiation (Welch et al., 1986,
1988) and cell surface and 2-dimensional gel protein patterns
(Welch et al., 1988). Some of the populations were more
malignant (i.e. metastatic) and some were less malignant
than the primary tumour. Likewise, there was no trend
towards increased resistance or sensitivity to a single thera-
peutic approach.
Significant differences in cell surface properties (Welch et
al., 1988) of the locally recurrent tumours (both gains and
losses) suggest that the antigenic profiles of locally recurrent
tumour cells are different. Hence, one could suppose differ-
ences in cellular recognition by host defense mechanisms.
Furthermore, a significant leukocyte infiltration into the
primary (MTF7) tumour (Neri et al., 1982; Estrada et al.,
1986) indicated that there was an immune response although
ineffectual. Some of the inability of the immune system to
cure is probably due to the overwhelming mass of the
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tumour (Hersh et al., 1980). Yet after removing a large
portion (>>99%) of the tumour mass surgically, several rats
still developed local recurrences which likewise exhibited
marked immune cell infiltration. Therefore, we wanted to
measure the sensitivity of the local recurrent tumour cell
lines to polymorphonuclear cell (PMN), macrophage and
natural killer cell (NK) cytolysis in order to determine
whether locally recurring mammary tumours were more
resistant to immune cell killing than the primary tumour. We
also wanted to determine whether any changes in sensitivity
to immune cell cytolysis correlated with changes in meta-
static potential of the locally recurring tumours. Finally, we
wanted to determine whether changes in immune cell sensi-
tivity, if any, would be important determinants in designing
immunotherapy protocols used to treat recurrent tumours.
Our results showed that recurrent tumours have often differ-
ent sensitivities to immune cell cytolysis, but that there is no
trend toward more or less sensitivity. The data also showed
that nonspecific activation of natural killer cell populations
may not be effective against all tumour subpopulations.
Materials and methods
Animals
Virus- and pathogen-free Fischer 344/NHsd rats were
obtained from Harlan Sprague-Dawley (Indianapolis, IN).
The rats were maintained under specific pathogen free
conditions (P3) under the guidelines of the National Insti-
tutes of Health and the Upjohn Company. Animals were fed
(Purina Rodent Chow) and given water (<10 parts per
million chlorine) ad libitum.
Cell lines and tissue culture
Locally recurrent sublines were developed from 13762NF
mammary adenocarcinoma local tumour-derived clone
MTF7 (Neri et al., 1982) as previously described (Estrada et
al., 1986) and depicted in Figure 1. Briefly, MTF7(T20) was
injected into the left inguinal mammary fat pad of age-
matched syngeneic female F344/NHsd rats and allowed to
grow for 23 days. Resulting tumours were removed from
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individual rats under metofane (methoxyflurane, Pitman
Moore, Washington Crossing, NJ) anaesthesia and estab-
lished in tissue culture (scl and sc3). Some of the rats
developed recurrent tumours at the site of surgical excision
within 14 days. These were established in tissue culture (LR1
from the animal bearing scl and LR3 from the animal
bearing sc3). Also, LRIa was established in tissue culture
from a local recurrence of LR1.
Cells were grown in alpha-modified minimum essential
medium (AMEM; Irvine Scientific, Irvine, CA) supple-
mented with 5% foetal bovine serum (Biocell, Carson, CA)
and no antibiotics (cAMEM) in a 37°C humidified atmos-
phere containing 5% CO2. Cells were routinely grown in
100mm dishes (Corning Glass Works, Oneonta, NY) and
passaged using 0.25% trypsin (GIBCO, Grand Island, NY)
at a split ratio of 1:50 when the cultures became 80%
confluent. All cell lines were routinely screened and found to
be free of Mycoplasma contamination (Chen, 1977). The cell
lines were also checked for virus contamination (by Micro-
biological Associates) and found to be free of Sendai, MHV,
PVM :Reo3, ectromelia, MVM, polyoma and lactate
dehydrogenase and lymphatic choriomeningitis viruses.
Radiolabelling of tumour cells
Cells were labeled according to the method of Fidler (1970)
with slight modifications. Media was replaced on sub-
confluent cultures with cAMEM containing 0.3pCiml-P of
[125-I]-UdR (ICN, Costa Mesa, CA) 24h prior to use. Under
these conditions labeling was routinely between 0.2-0.4cpm/
cell. Prior to detachment, monolayers were rinsed 3 x with
prewarmed calcium- and magnesium-free Dulbecco's phos-
phate buffered saline (CMF-DPBS) to remove unincorpor-
ated label.
Isolation of rat immune cells
Polymorphonuclear cells (PMN) Syngeneic F344/NHsd rats
were injected i.p. with 5ml of sterile 10% proteose peptone
solution (Difco, Detroit, MI). Four to 8 h later, the rats were
sacrificed and peritoneal exudate was collected. PMN were
obtained from the cell pellet following centrifugation over a
Ficoll-Paque (Pharmacia, Piscataway, NJ) gradient. Conta-
minating RBC were lysed with RBC lysis buffer (0.15 M
NH4Cl, 10mM KHCO3, 0.1mM disodium EDTA, pH 7.4)
and the PMN washed in CMF-DPBS, counted on a haema-
cytometer, and adjusted to desired concentration in
cAMEM. This method consistently yielded >98% PMN
which were functionally active (i.e. degranulation and oxygen
radical production in response to f-Met-Leu-Phe (FMLP;
Sigma Chemical Company, St. Louis, MO) and/or phorbol
myristate acetate (PMA; L.C. Services, Woburn, MA)) and
viable for at least 24h by the trypan blue dye exclusion test
(Aeed & Welch, unpublished observations).
Macrophages F344/NHsd rats were injected with 5ml
sterile 10% thioglycollate broth (Difco). Three or 4 days
later, syngeneic macrophages were harvested by a peritoneal
wash with 10ml Hank's balanced salt solution (HBSS,
GIBCO), pH 7.2, according to the method of North &
Nicolson (1985) with minor modifications. The peritoneal
exudate cells (PEC) were washed with HBSS and resus-
pended at a concentration of 6.67 x 104 cells ml-1 cAMEM
and placed in 100mm dishes. After a 2h incubation at 37°C
in a humidified atmosphere, the plates were washed with
warm CMF-DPBS to remove non-adherent cells. The adher-
ent cells, mostly macrophages by morphological criteria and
nonspecific esterase activity, were then harvested from the
dishes by adding 5ml of 10mM EDTA in CMF-DPBS and
incubation for 15min at 37°C. Then, with the aid of a cell
scraper, macrophages were detached and resuspended in
cAMEM and adjusted to desired concentration. No antibio-
tics were used in any of these procedures.
Natural killer cells (NK) Syngeneic NK cells were collected
by the method of Li et al., (1987) with slight modification.
F344 rats were injected i.p. with 10ml HBSS containing
5 Uml-1 bovine lung heparin (the Upjohn Company,
Kalamazoo, MI). Immediately following injection, the peri-
toneum was massaged for 30 to 60 sec and PEC were
removed, washed in sterile HBSS without heparin and
suspended in cAMEM. The cells were then counted on a
haemacytometer and adjusted to desired concentration. For
stimulated NK, rats received either 50, 100 or 200mgkg-1
bropirimine, also known as ABPP [2-amino-5-bromo-6-
phenyl-4(3H)-pyrimidinone] or U-54,461, (Wierenga et al.,
1980) in 0.5ml sterile vehicle 100 (the Upjohn Company) 3
days prior to NK isolation (Lotzova et al., 1983). For some
experiments, peritoneal exudate cells were 'activated' in vitro
with varying concentrations of rat IL-2 (Sigma, St. Louis,
MO) which is one of the most potent NK cell activators
known (Chun et al., 1985).
PMN and macrophage cytolysis assays
PMN were prepared and added to quadruplicate wells in
Corning 24-well tissue culture plates which had been seeded
2-4h previously with 10,000 radiolabeled tumour cells. After
adding PMN cells at the appropriate effector:target (E:T)
ratios (total volume of 1 ml/well) the plates were covered and
incubated at 37°C for 24h for PMN, and for 24, 48 or 72h
for macrophage cytolysis. Macrophage cytolysis assays were
performed according to previously published methods
(North & Nicolson, 1985) with slight modifications. Briefly,
macrophages were activated with 50ngml - I lipopoly-
saccharide (LPS; Sigma) added to each well. After incuba-
tion 900jul aliquots of supernatant were gamma counted for
experimental cpm released.
Specific cytolysis was calculated according to the following
equation:
% ~ cytotoicity =Test cpm -spontaneous release cpm 100
Total cpm -spontaneous release cpm
where test cpm, spontaneous release cpm, and total cpm
represent the radioactivity in 900p1 aliquots of the superna-
tant from the effector and target cell mixture, the superna-
tant of target cells alone, and lysed target cells alone.
NK cytolysis assay
We measured susceptibility of locally recurrent 13762NF
mammary adenocarcinoma cell sublines ~o unstimulated and
ABPP-stimulated NK cytolysis using the method of Li et al.
(1987) with minor modifications. To obtain stimulated NK
cells, rats were injected i.p. with either 50, 100 or
200mgkg- bropirimine three days prior to cell collection.
Effector cells were prepared and added to quadruplicate
wells in Corning 96-well U-bottom tissue culture microtiter
plates which had been seeded 2-4h previously with 50,000
radiolabelled tumour cells. At the same time, identical
cultures of YAC-IA cells (kindly provided by Dr L.H. Li,
the Upjohn Company) were prepared as a positive control.
YAC-IA were grown and labeled in RPMI-1640 medium
(GIBCO) until immediately prior to use in the NK cytolysis
assay. After adding NK cells at the appropriate effector:
target ratios (total volume of 200,p1/well), the plates were
covered and centrifuged at 200g for 5min and incubated at
37°C for 4h. After incubation the plates were centrifuged
again, 150pl aliquots of supernatant were prepared and
counted using a Packard gamma counter for experimental
cpm released, and cytolysis calculated as above. A sterile
vehicle control was included in all NK studies and found not
to differ from uninjected rats.
Results
PMN cytolysis









Figure 1 Schematic representation of the derivation of 13762NF
mammary adenocarcinoma locally recurrent cell lines.
Table I Syngeneic polymorphonuclear cell lysis of locally recurrent
13762NF mammary adenocarcinoma cell linesa.
Percent cytolysis
Effector: Target cell ratio
Experiment * I Experiment * 2
Cell line 10:1 20:1 10:1 20:1
MTF7 1.1 2.3 2.2 4.1
scl 0 0 0 1.1
LRI 0 0 0 0
LRla 0 0 0 0
sc3 10.1 1.1 2.8 6.8
LR3 16.7 14.0 10.3 12.5
a1 x 104 [125I]UdR labeled tumour cells were incubated with PMN
for 24h at 37°C in a humidified atmosphere. Percent cytolysis was
determined according to the following equation:
Test cpm -spontaneous release cpm
x 100.
Total cpm -spontaneous release cpm
for any of the cell lines tested. Maximum cytolysis was
16.7% for LR3 at E:T ratios of 10:1 and 14% at 20:1.
There was no distinct E: T dose-response for any of the cell
lines, thus the cytolysis observed was probably nonspecific.
In other studies (Aeed et al., 1988) the maximum PMN-
mediated cytolysis of 13762NF mammary adenocarcinoma
cells was 7.5% in poorly metastatic clone at E:T of 100:1.
Stimulation of PMN with PMA did not increase their ability
to cytolyse 13762NF mammary adenocarcinoma cell clones
or locally recurrent tumour cell lines (data not shown).
Macrophage cytolysis
There was no appreciable cytolysis using unstimulated
macrophages at any E:T or co-incubation time (data not
shown) which also confirms previously reported observations
(North & Nicolson, 1985). Using LPS-activated macro-
phages, there was generally no macrophage mediated cytoly-
sis of any cells at incubation times of 24 and 48 h (Table II).
At 72h, however, MTF7, scl, and LR1 were maximally
lysed at 25.1%, 38.7% and 58.8% at E:T ratio of 20:1
(Table II). MTF7 cytolysis sensitivity was similar to that
previously described at 72h and at comparable E:T (North
& Nicolson, 1985). LR1 was lysed at a significantly
(P<0.05) higher level than scl, and both were lysed at
significantly higher levels than the 'parental' MTF7 line.
Maximal lysis for LRIa, sc3 and LR3 ranged from 0 to
4.4%. Thus, there are locally recurrent lines that are more
sensitive (scl and LR1) and more resistant (sc3, LR3 and
LRla) than MTF7 to activated macrophage cytolysis.
Table II Syngeneic macrophage cytolysis of locally recurrent




time (h) line 5:1 10:1 20:1
24 MTF7 0 0 0
scI 0.1 0 0
LR1 3.0 0 0
LRla 4.9 0 0.5
sc3 0 1.2 2.5
LR3 0 1.3 0
48 MTF7 0 0.7 0.4
scI 0 0 0
LR1 4.8 0 0
LRIa 4.9 0 0
sc3 0 0.9 0
LR3 0 0 0
72 MTF7 14.6 12.7 17.4
sci 21.9 23.8b 38.7b
LRI 40.7b,c 40.3b,c 58.8b,C
LR1a Ob,c,d Ob,c,d Ob,c,d
sc3 ob 1.8b 30b
LR3 2.8b 4.4b 6.3b
a1 x 104 [125I]UdR labeled tumour cells were co-incubated with
LPS-activated for 24h at 37°C in a humidified atmosphere. Label
released was used to determine specific cytolysis according to the
following equation:
Test cpm -spontaneous release cpm
C cttxcty= x 0 Total cpm-spontaneous release cpm
bSignificantly different (P<0.05) from MTF7 at the same E:T ratio
using Student's t-test; cSignificantly different (P<0.05) from scl at
the same E:T ratio; dSignificantly different (P<0.05) from LRI at
the same E:T ratio.
NK cytolysis
Most of the locally recurrent mammary tumours are not
lysed by naive, syngeneic NK cells at E:T up to 100:1
(Figure 2). Maximal cytolysis was 4% for LR3 and the range
for all locally recurrent cell lines was 0.5-4.0%. If a nonspe-
cific immunomodulator, bropirimine, is used to activate NK
cells prior to isolation (Lotzova et al., 1983), there is a slight
increase in the ability of NK cells to cause 13762NF
mammary adenocarcinoma cell killing, mostly at the highest
E:T levels. ABPP-elicited NK cells caused up to 28% killing
for sc3, but only at E:T of 100:1. Killing was well under
20% for all of the other LR sublines and parents at all of
the E:T tested. In contrast, bropirimine-activated NK cells
are able to kill 50% to almost 100% of YAC-IA cells at low
(20:1) effector to target ratios (Figure 1 & Table III). In
separate experiments, E:T ratios up to 50:1 with the potent
NK cell activator IL-2 alone or in combination with bropiri-
mine resulted in a maximum tumour cell kill of 17%
(Table III). Use of NK cells activated with combinations of
bropirimine and IL-2 were no more effective at killing
13762NF mammary adenocarcinoma cells or YAC-la cells
than either drug alone for the most part (Table III).
Discussion
It is now well accepted that most solid tumours are com-
prised of a heterogeneous mixture of cells which differ for
multiple phenotypes (Heppner, 1984). Likewise, it is becom-
ing increasingly clear that tumour composition changes
during the course of tumour growth and progression (Neri &
Nicolson, 1981; and reviewed in Welch & Tomasovic, 1985;
Nicolson, 1987). The implications of dynamic heterogeneity
have been discussed and widely studied; however, the mecha-
nisms involved in controlling tumour diversification and





























Figure 2 Sensitivity of 13762NF rat mammary adenocarcinoma
locally recurrent cell lines and clones to ABPP-stimulated NK
cytolysis in vitro. Rats were injected i.p. three days prior to NK
cell harvest with SV100 containing varying concentrations of
ABPP. Cytolysis was determined by measuring cpm released
from [125I]-UdR-labeled tumour cells in 96-well microtitre plates.
Bars represent mean of quadruplicate samples (s.e.m. is <5%
for all points). Open bars (O) represent E:T of 10:1; slashed
bars (0), E:T=20:1; solid bars (-), E:T=50:1; and cross-
hatched bars (n), E:T=100:1. Please note different scale for
YAC-1A cells compared to rat adenocarcinoma cell lines.
impact of changing tumour composition is still being deter-
mined. It is already known that the generation and mainten-
ance of heterogeneity are both tumour cell directed and
tumour cell response to external environment (Welch, 1987,
1988; Welch & Tomasovic, 1985). Neoplastic cells are extre-
mely unstable and generate variants at high rates in what
appears to be a preprogrammed manner (reviewed in Welch
& Tomasovic, 1985). The composition of a tumour is
regulated by interactions with host cells and selective pres-
sures which eliminate some variants spontaneously generated
by tumour subpopulations.
The most obvious interaction (i.e. selective pressure)
between neoplastic cells and normal cells occurs with the
immune system (Fidler & Kripke, 1980). Immune cells
respond to subsets of tumour cells and eliminate immuno-
genic portions of the tumour mass. Besides host selective
pressures, artificial selective pressures (i.e. therapy) can also
reduce tumour mass. One could predict differences between
tumours analyzed prior to and after therapy and that the
latter would be more resistant to the same follow-up treat-
ment (Goldie & Coldman, 1984). Immune cells also are
involved in changing properties of tumour cells by nontoxic
mechanisms. For example, heterotypic embolus formation
(Liotta et al., 1976, Fidler et al., 1979), use of enzymes
secreted by immune cells (Aeed et al., 1988; Dabbous et al.,
1986) and undetermined mechanisms are involved in chan-
ging metastatic potential (Fidler et al., 1979). Therefore,
these studies were designed to address the connection, if any,
between immune cell responsiveness before and after surgery
(well after effects of drugs, anaesthetic etc. were past). Since
locally recurrent tumours often differ in malignant potentials
and sensitivities to follow-up therapy, we hypothesized that
some of the changes may be related, in part, to changes in
sensitivity to immune cell killing.
Cancer therapy currently involves debulking (often with
surgery, but also with radiation, chemotherapy and/or
immunotherapy) and 'mopping up' with radiation therapy,
chemotherapy or immunotherapy. Drift of tumour popula-
tions indicates that follow-up therapy may need to account
for shifting populations or different proportions of subpopu-
lations than were present in the primary tumour, therefore
changes in sensitivities to individual treatment arms would
be observed. Our previous results confirmed this hypothesis
since locally recurrent tumour-derived sublines were appar-
ently randomly assorted from the primary tumour for meta-
static potentials (Estrada et al., 1986) and commonly used
chemotherapy and radiation therapy approaches (Welch et
al., 1986; 1988). There was some predictability in the pheno-
typic drift since many recurrences were indeed more resistant
to 5-fluoro-2'-deoxyuridine (at the LD90 dose) compared to
the primary tumours (Welch et al., 1988). Also, there were
some common shifts in 2-dimensional and cell surface pro-
tein patterns for all of the recurrences compared to the
primary (MTF7) cell line, in particular was the progressive
loss of a Mr`%93,000kDa sialoglycoprotein in all of the
recurrences (Welch et al., 1988). Besides selection with
artificial 'selective pressures' we also wanted to determine
whether recurrent tumours were more or less susceptible to
nonspecifically activated host immune cells. As a corollary,
we wanted to address a basic question: are nonspecifically
activated (i.e. by therapeutic intervention) immune cells
effective against all target cells?
13762NF mammary adenocarcinoma locally recurrent
tumours regrew after significant surgical elimination of a
large part of the tumour mass. Syngeneic F344/NHsd rats
mounted an immune response to the primary MTF7 tumour
but it was inadequate to prevent tumour growth. Several
local recurrences elicited marked immune infiltration as well,
but there was significant heterogeneity in the host response
(Estrada et al., 1986). Leukocyte infiltration generally
appeared to increase in recurrences compared to the primary
tumour in most cases; however, some tumour lines elicited
less infiltration. And there was also evidence of zonal
heterogeneity in host response which was apparent in differ-
ent histologic sections.
Several immune cells have been shown to play a role in
the metastatic properties of tumour cells (Fidler et al., 1979;
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Table III Cytolysis of IL-2- and ABPP-stimulated NK cells on locally recurrent rat mammary adenocarcinoma
cell linesa.
Treatment Percent cytolysis
ABPP IL-2(IUml-1) E: Tb MTF7 scl LR LRa sc3 LR3 YAC-la
- 0:1 1 0 0 1 1 2 3
20:1 3 0 1 1 1 11 23
50:1 6 1 0 0 1 10 26
- 0.30 0:1 1 0 0 0 1 6 4
20:1 2 1 1 1 3 10 27
50:1 6 1 1 0 3 12 28
- 3.00 0:1 2 0 0 0 0 5 3
20:1 5 1 1 1 2 10 28
50:1 NDC ND ND ND ND ND ND
- 30.0 0:1 0 0 0 1 1 7 1
20:1 0 1 1 1 2 7 12
50:1 2 2 1 1 2 11 53
+ 0:1 1 0 0 0 0 7 4
20:1 1 1 1 1 2 9 25
50:1 2 9 4 2 11 14 49
+ 0.30 0:1 3 0 0 0 0 5 3
20:1 3 1 1 1 2 9 27
50:1 5 9 12 3 11 15 38
+ 3.00 0:1 4 0 0 0 0 7 7
20:1 1 8 3 1 1 10 25
50:1 2 7 2 5 11 15 38
+ 30.0 0:1 2 0 0 0 0 6 3
20:1 0 1 1 2 0 8 30
50:1 1 8 7 4 9 17 50
a1 x 104 ['251]UdR-labeled tumour cells were co-incubated with NK cells activated with 200mgkg1 ABPP i.p.
in vivo 3 days prior to harvest, in vitro with IL-2, or both for 4h at 37°C. Percent cytolysis was determined by
the following formula:
Test cpm-spontaneous release cpm
Totalcpm-spontaneous releasecpm
bEffector to target cell ratio; CND, not determined.
Dabbous et al., 1986; Aeed et al., 1988). Effects can be either
stimulatory or inhibitory depending upon immune cell type
and tumour cell type (Fidler et al., 1979). Hanna and
colleagues have shown that NK cells are highly efficient at
clearing tumour cells from the circulation and susceptibility
of tumour cells to NK-mediated killing is often, but not
always, inversely correlated with metastatic potential
(Hanna, 1982; 1985). In the 13762NF mammary adeno-
carcinoma system none of the cells are susceptible to NK
killing at high E:T ratios even when NK activity is enhanced
by the immunomodulators bropirimine and/or interleukin-2.
Despite possessing highly heterogeneous metastatic poten-
tials, NK resistance of LR cell lines is identical, indicating
that this is not a property correlative of metastatic potential
in the 13762NF mammary adenocarcinoma locally recurrent
tumour model system. Similarly, NK susceptibility does not
change as recurrent sublines are selected from primary
tumour growths.
It is interesting to note that administration of bropirimine
to rats 3 days prior to NK harvest or addition of
interleukin-2 to the culture medium resulted in marked
activation of NK cells for cytolysis of YAC-IA cells. There
was also a weak, dose-dependent increase in 13762NF
mammary adenocarcinoma cell killing, but this was un-
remarkable (Figure 2 & Table III). Maximal cytolysis for
mammary tumour cells was 28% (in only one experiment)
compared to 50->90% for the YAC-IA cell line. This
demonstrates that, despite complete activation, NK cells do
not become capable of eliminating ALL tumour cells,
especially those resistant initially.
Gorelik et al. (1982) showed that co-injection of macro-
phages with B16 melanoma or Lewis lung carcinoma (3LL)
tumour cells resulted in increased pulmonary colonization.
Similarly, Starkey et al. (1984) showed that heterotypic
aggregates containing PMN or macrophages and rat hepato-
carcinoma cells were more capable of pulmonary coloniza-
tion than tumour cells alone. These data show that tumour
cells cooperate with some immune cells to enhance properties
important for metastatic colonization. On the other hand,
Fidler, Poste & colleagues have examined the role of acti-
vated macrophages in the prevention and elimination of B16
melanoma metastases (Fidler et al., 1985; Poste, 1984). They
have found that liposome-activated macrophages (muramyl
dipeptide-containing liposomes) are capable of preventing
and eradicating established micrometastases. North &
Nicolson (1985) found that there was no correlation between
metastatic potential of 13762NF mammary adenocarcinoma
cell clones and sensitivity to LPS-activated-macrophage-
mediated cell lysis, intratumoural macrophages or thiogly-
colate-elicited macrophages. Our conclusions are similar with
the recently derived locally recurrent tumour model. MTF7
and LR3 form approximately the same number lung colonies
(>200 metastases per rat (Estrada et al., 1986) yet 20-25%
of MTF7 versus 0-4% of LR3 cells are killed in a macro-
phage cytolysis assay. scl and sc3 form approximately one-
half as many lung colonies as MTF7 but macrophage killing
occurs for 22-38% and 0-3% of the cells, respectively.
Likewise, there is no pattern towards increased or decreased
sensitivity to macrophage killing in the local recurrence
lineages.
Polymorphonuclear cells make up a large percentage of
the circulating leukocytes in human blood; however, PMN
account for only 10-20% of circulating white blood cells in
F344/NHsd rats. We have shown that PMN levels in the
blood rise sharply in 13762NF mammary adenocarcinoma
tumour-bearing rats and the increase is proportional to the
metastatic potential of the tumour. The circulating neutro-
phils secrete high levels of collagenase IV and a heparan
sulphate endoglycosidase suggesting that they may be assis-
ting tumour cell extravasation (Aeed et al., 1988). Glaves
(1983) found that activation of PMN in the vasculature with
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production and increased radiolabeled tumour cell clearance
following intravenous inoculation. She proposed that PMN
may be important in limiting metastatic potential by elimi-
nating circulating B16 melanoma cells. While PMN in our
experiments are completely active in that they respond to
PMA and FMLP to degranulate or produce oxygen metabo-
lites, they are essentially unable to kill 13762NF mammary
adenocarcinoma locally recurrent tumour cells in the
presence or absence of these agents. Others have shown that
PMN are capable of killing tumour cells (Pickaver et al.,
1972; Kondo et al., 1986; Lichenstein, 1987; Lichenstein &
Kahle, 1985; Morikawa et al., 1985). As with NK cells and
macrophages, there was no trend towards increased resis-
tance with the local recurrent lineages tested.
All of the results presented here are the result of inter-
actions between a single immune cell type with tumour cells.
Lack of cytotoxicity with NK or PMN may have limited
meaning since there may be synergy in vivo. The results do,
within these limits, allow direct comparison of sensitivities
under the conditions described and the sensitivities are
significantly different. Extrapolation to the complex situation
in an immunocompetent host is difficult.
In summary, locally recurrent tumours differ significantly
from the primary tumour for a variety of properties, includ-
ing sensitivity to natural immune mechanisms. Some recur-
rences were significantly more sensitive to macrophage
mediated cell killing while others were significantly more
resistant. None of the 13762NF mammary adenocarcinoma
sublines were sensitive to activated NK or PMN cell killing.
And there was no apparent correlation in the sensitivity of a
single cell line to one immune cell type to another immune
cell type. These results imply that changes in cellular compo-
sition of locally recurrent tumours may overwhelm the
body's ability to adapt to and to mount an effective immune
response against all survivors. They do not imply that all of
the recurrences are resistant to immune cell killing. Some, in
fact, may be more sensitive. Our results do demonstrate that
follow-up therapy for recurrent tumours, even treatment
with nonspecific immunomodulators, must account for
changes in tumour composition.
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